Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Faecal microbiota transplantation in Crohn's disease: an Australian randomised placebo-controlled trial protocol
Publication Year: 2025 Source: BMJ Open PMID: 40254304
INTRODUCTION: The enteric microbiota drives inflammation in Crohn's disease. Yet, there are no placebo controlled trials evaluating the efficacy and safety of faecal microbiota transplantation (FMT) in inducing and maintaining remission in patients with active Crohn's disease. The Microbial Restoration (MIRO) study aims to establish this evidence. METHODS AND ANALYSIS: …
Unravelling the causality between inflammatory bowel disease and polycystic ovary syndrome mediated by gut microbiota and blood metabolism: insights from two prospective cohort studies
Publication Year: 2025 Source: Gut PMID: 40254336
No Abstract
Prevalence of extraintestinal manifestations and other associated conditions in a cohort of patients with inflammatory bowel disease at an advanced specialty center in Bogotá, Colombia
Publication Year: 2025 Source: Rev Gastroenterol Mex (Engl Ed) PMID: 40254485 DOI: 10.1016/j.rgmxen.2024.07.002
INTRODUCTION AND AIMS: The prevalence and incidence of inflammatory bowel disease (IBD) has increased significantly in Latin America. Extraintestinal manifestations (EIMs) have elevated morbidity and are poorly characterized in the region. Our aim was to describe the characteristics of EIMs in patients with IBD at the Hospital Universitario Fundacion Santa …
Advancing histological evaluation in IBD: New perspectives on Claudin-2 and mucosal healing
Publication Year: 2025 Source: Dig Liver Dis PMID: 40254492 DOI: 10.1016/j.dld.2025.04.003
No Abstract
Oncologic outcomes of surgically treated colorectal cancer in octogenarians: a comparative study using inverse probability of treatment weighting (IPTW)
Publication Year: 2025 Source: BMC Gastroenterol PMID: 40254572
PURPOSE: Octogenarians constitute a growing number of diagnoses for colorectal cancer. However, the optimal treatment for these increasingly vulnerable octogenarians with colorectal cancer remains a challenging issue. The aim of this study was to evaluate the oncologic outcomes of colorectal cancer, comparing octogenarians (> 80 years) and younger age (60-79 …
A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model
Publication Year: 2025 Source: Sci Rep PMID: 40254678
Parenteral nutrition (PN) is lifesaving for patients with short bowel syndrome and other gastrointestinal disorders, however long-term use may lead to complications including hepatosteatosis and sepsis. We have previously demonstrated the anti-steatotic, -fibrotic, and -inflammatory properties of SEFA-6179, an engineered medium-chain fatty acid analogue. We hypothesized that SEFA-6179 treatment would …
TaxSEA: rapid interpretation of microbiome alterations using taxon set enrichment analysis and public databases
Publication Year: 2025 Source: Brief Bioinform PMID: 40254830
Microbial communities are essential regulators of ecosystem function, with their composition commonly assessed through DNA sequencing. Most current tools focus on detecting changes among individual taxa (e.g. species or genera), however in other omics fields, such as transcriptomics, enrichment analyses like gene set enrichment analysis are commonly used to uncover …
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
Publication Year: 2025 Source: Gut Liver PMID: 40254990
BACKGROUND/AIMS: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from intravenous (IV) infliximab using real-world data are lacking. We aimed …
Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study
Publication Year: 2025 Source: Mol Nutr Food Res PMID: 40255128 DOI: 10.1002/mnfr.70067
This study aimed at investigating the effects of pomegranate juice (POMJ) consumption on inflammatory biomarkers and gene expression in patients with inflammatory bowel disease (IBD) in clinical remission. In this randomized, placebo-controlled trial, 16 subjects with IBD in remission consumed POMJ or placebo for 12 weeks. POMJ consumption significantly reduced …
5-Aminosalicylates for non-surgical patients with active or quiescent Crohn's disease: an overview of systematic reviews (umbrella review)
Publication Year: 2025 Source: J Crohns Colitis PMID: 40255145
BACKGROUND: 5-aminosalicylates (5-ASAs) are commonly used in non-surgical patients with Crohn's disease (CD), especially in mild-to-moderate disease, despite current guidelines against their use. Despite this, the evidence regarding their efficacy is mixed, with conflicting findings in systematic reviews (SRs). AIMS: We conducted an overview of reviews (umbrella review) to consolidate …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide